BTKi have the potential to affect disease progression and disability in MS by targeting microglia, although it remains unclear whether the effect is mediated through suppression of inflammation and/or promotion of neuroprotection, and whether the effect is mediated by microglia, astrocytes, or both [8,10]. Here, IBTK is linked to myeloid sarcoma.